3EO 3TR technology enables up to 70% savings versus existing point of care molecular tests.
This funding enables 3EO to quickly build upon its current high-performing low-cost platform.
The funding supports meaningful movement toward making molecular testing more universally accessible, reducing inequities in care.
BOSTON–(BUSINESS WIRE)–3EO Health, a “Point of Life” diagnostics company focused on the development of high-performing low-cost molecular diagnostics for both the point of care and community settings, is excited to announce its successful selection for a highly competitive Rapid Acceleration of Diagnostics (RADx®) Tech award by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the National Institutes of Health (NIH). This prestigious grant, with its substantial financial support, will fuel 3EO Health’s expansion to develop a highly affordable, top-performing over-the-counter molecular multiplex respiratory diagnostic test capable of rapidly identifying Influenza A, Influenza B, and COVID- 19—all from a single swab in a single test.
The RADx Tech program, administered by NIBIB, is at the forefront of advancing groundbreaking diagnostic technologies to address critical public health challenges, including the ongoing COVID-19 pandemic. 3EO Health’s selection underscores the potential of their low-cost, high-performance innovative approach to enabling diagnostics for all.
With the NIH RADx Tech award, 3EO Health will accelerate and expand the development and application of its novel 3TR technology into a multiplex format. 3EO’s 3TR technology fundamentally shifts the cost equation for molecular testing enabling up to a 70% reduction in cost versus prevailing medical technologies while delivering improved ease of use. This exponential reduction in cost enables the deployment of molecular technology for utilization in more homes and community locations.
“We are honored to be chosen as recipients of the RADx Tech award from NIBIB,” said Jeremy Schubert, CEO of 3EO Health. “This award is a testament to our dedication to unlocking access to diagnostic testing for all. Our 3TR technology enables testing in more locations for more communities.”
With this award, 3EO Health will accelerate its multiplex development efforts and optimize production processes, to ensure the rapid development of this vital diagnostic test.
“3EO Health’s innovative approach holds immense promise for the future of diagnostic testing,” said Peter Honkanen M.S.M., B.S.E.E., Chief Technology officer of 3EO Health. “Our solution has the potential to make a significant impact not only in addressing respiratory illnesses but also in expanding overall healthcare accessibility.”
This project has been funded in part with Federal funds from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health, Department of Health and Human Services, under Contract No. 75N92023D00001.
For more information about 3EO Health and its 3TR Technology, please visit 3EOhealth.com.
3EO Health Inc. is a “Point of Life” diagnostic company leveraging novel technology to exponentially lower cost and expand clinical and community access to high impact diagnostic tools. Our passion is to create a world where every person is empowered to optimize health – for their patients, communities, family, and self. We seek to ensure physicians and consumers have equitable access to the best technology that is both affordable and easy to use. We enable people to thrive by extending the four walls of the health system into the community, work, and home. Our mantra is “… the right information, in the right place, at the right time, enabling the right action, right now.” For more information visit 3EOhealth.com.
For all inquiries, please contact:
Melyssa St. Michael